Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial

Table 3 Change of secondary outcome measures in risperidone long acting injection and paliperidone palmitate groups

	RLAI group				PP group				Difference in change between groups
	Baseline		Change		Baseline		Change		p	Partial eta-squared	95%CI
	Mean	SD	Mean	SD	Mean	SD	Mean	SD
SWNS
Total score	79.09	19.93	−.09	19.58	67.00	19.25	3.20	7.36	.655	.012	−9.07 to 14.06
Mental function	16.00	4.52	−.18	4.58	12.60	3.92	.70	3.02	.990	< .001	−3.74 to 3.69
Self-control	15.45	4.44	1.46	5.18	14.20	3.49	.40	3.13	.267	.072	−1.91 to 6.48
Emotional regulation	16.55	4.06	−1.91	3.73	13.20	3.77	1.80	1.93	.034*	.238	−5.90 to -.26
Physical functioning	15.64	5.32	−1.27	5.95	13.80	4.54	.30	2.50	.825	.003	−4.89 to 3.951
Social integration	15.36	5.63	−.36	4.37	13.40	4.86	.00	2.16	.492	.028	−1.69 to 3.38
PANSS
Total	83.00	19.88	−5.09	8.18	78.10	21.02	−1.70	5.08	.349	.049	−8.90 to 3.31
Positive	18.64	5.32	−2.00	2.65	16.30	4.72	−.30	2.00	.222	.082	−3.39 to .84
Negative	21.73	5.14	−.73	1.10	20.10	6.06	.20	1.62	.136	.119	−2.27 to .34
General psychopathology	42.64	10.88	−2.36	5.45	41.70	11.05	−1.60	2.50	.732	.007	−4.39 to 3.14
DIEPSS total	2.55	2.60	−.09	.30	0.90	1.28	.30	1.06	.220	.082	−1.23 to .30
Total antipsychotic dose^a	432	112.6	−12.6	18.6	342	94.7	−26.8	52.0	.651	.012	−30.41 to 47.43

ISSN: 1471-244X